Baidu
map

Cardiovasc Diabetol:普通人群糖化血红蛋白A1c水平与心血管结局的关系,全民HA1c筛查或成趋势!

2021-11-17 MedSci原创 MedSci原创

在非糖尿病参与者中,糖化血红蛋白水平升高与心血管疾病发病率和总死亡率相关,强调了糖化血红蛋白水平在整个人群中的重要性。

评估普通人群的血管风险对临床决策很重要,尽管临床已经发现了很多新的独立的生物标志物,但心血管风险的评估依然依赖于一组传统的心血管风险因素(CVRFs),如年龄、性别、血压、血脂水平、糖尿病(DM)和吸烟等。是否在心血管风险评估中纳入新的生物标记仍然是一个值得争论和研究的话题。

糖尿病被认为是心血管疾病(CVD)的经典危险因素。为了改善心血管风险评估及探索新的危险因素,糖化血红蛋白或血红蛋白A1c (HbA1c)可能是一个潜在的候选者,在普通人群中,其与心血管结果的关联强度仍不确定。本研究旨在评估普通人群中糖化血红蛋白与心血管结局的相关性。

研究者对来自欧洲的6项前瞻性人群队列研究的数据进行了分析,其中包括36180名参与者。在无糖尿病(N=32496)和糖尿病(N=3684)的受试者中,结合经典心血管风险因素(CVRFs)评估HbA1c与心血管死亡率、心血管疾病(CVD)发病率和总死亡率的相关性。

Kaplan-Meier曲线显示随着HbA1c水平的升高,心血管事件发生率更高。Cox回归分析显示总研究人群中HbA1c(单位:mmol/mol)与检查结果之间存在显著相关性。因此,HbA1c每增加10 mmol/mol,心血管死亡率的危险比(HR)为1.16,CVD发病率为1.13,总死亡率为1.09。

HbA1c与事件发生时间之间关联的三次样条

在无糖尿病且HbA1c水平升高的研究参与者中,也观察到与CVD发病率和总死亡率的相关性。心血管死亡率、心血管疾病发病率和总死亡率的HbA1c临界值分别为39.9 mmol/mol(5.8%)、36.6 mmol/mol(5.5%)和38.8 mmol/mol(5.7%),也显示风险增加。

总之,本研究显示糖化血红蛋白与欧洲普通人群的心血管死亡率、总死亡率和心血管疾病独立相关。糖化血红蛋白水平与预后之间的关系基本呈单调递增关系。在非糖尿病参与者中,糖化血红蛋白水平升高与心血管疾病发病率和总死亡率相关,强调了糖化血红蛋白水平在整个人群中监测的重要性。

参考文献:Sinning, C., Makarova, N., Völzke, H. et al. Association of glycated hemoglobin A1c levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium. Cardiovasc Diabetol 20, 223 (2021). https://doi.org/10.1186/s12933-021-01413-4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1939272, encodeId=223f19392e2f6, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Oct 07 06:29:17 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761774, encodeId=e3731e6177484, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Aug 02 19:29:17 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639971, encodeId=ca7016399e11a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Dec 01 16:29:17 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812547, encodeId=8a57181254e40, content=<a href='/topic/show?id=4ce08986996' target=_blank style='color:#2F92EE;'>#血红蛋白A1c#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89869, encryptionId=4ce08986996, topicName=血红蛋白A1c)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Feb 10 03:29:17 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269393, encodeId=9973126939344, content=<a href='/topic/show?id=49d1518915a' target=_blank style='color:#2F92EE;'>#心血管结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51891, encryptionId=49d1518915a, topicName=心血管结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Fri Nov 19 03:29:17 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614791, encodeId=ebb41614e9161, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Fri Nov 19 03:29:17 CST 2021, time=2021-11-19, status=1, ipAttribution=)]
    2022-10-07 quxin068
  2. [GetPortalCommentsPageByObjectIdResponse(id=1939272, encodeId=223f19392e2f6, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Oct 07 06:29:17 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761774, encodeId=e3731e6177484, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Aug 02 19:29:17 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639971, encodeId=ca7016399e11a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Dec 01 16:29:17 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812547, encodeId=8a57181254e40, content=<a href='/topic/show?id=4ce08986996' target=_blank style='color:#2F92EE;'>#血红蛋白A1c#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89869, encryptionId=4ce08986996, topicName=血红蛋白A1c)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Feb 10 03:29:17 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269393, encodeId=9973126939344, content=<a href='/topic/show?id=49d1518915a' target=_blank style='color:#2F92EE;'>#心血管结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51891, encryptionId=49d1518915a, topicName=心血管结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Fri Nov 19 03:29:17 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614791, encodeId=ebb41614e9161, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Fri Nov 19 03:29:17 CST 2021, time=2021-11-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1939272, encodeId=223f19392e2f6, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Oct 07 06:29:17 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761774, encodeId=e3731e6177484, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Aug 02 19:29:17 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639971, encodeId=ca7016399e11a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Dec 01 16:29:17 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812547, encodeId=8a57181254e40, content=<a href='/topic/show?id=4ce08986996' target=_blank style='color:#2F92EE;'>#血红蛋白A1c#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89869, encryptionId=4ce08986996, topicName=血红蛋白A1c)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Feb 10 03:29:17 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269393, encodeId=9973126939344, content=<a href='/topic/show?id=49d1518915a' target=_blank style='color:#2F92EE;'>#心血管结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51891, encryptionId=49d1518915a, topicName=心血管结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Fri Nov 19 03:29:17 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614791, encodeId=ebb41614e9161, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Fri Nov 19 03:29:17 CST 2021, time=2021-11-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1939272, encodeId=223f19392e2f6, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Oct 07 06:29:17 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761774, encodeId=e3731e6177484, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Aug 02 19:29:17 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639971, encodeId=ca7016399e11a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Dec 01 16:29:17 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812547, encodeId=8a57181254e40, content=<a href='/topic/show?id=4ce08986996' target=_blank style='color:#2F92EE;'>#血红蛋白A1c#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89869, encryptionId=4ce08986996, topicName=血红蛋白A1c)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Feb 10 03:29:17 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269393, encodeId=9973126939344, content=<a href='/topic/show?id=49d1518915a' target=_blank style='color:#2F92EE;'>#心血管结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51891, encryptionId=49d1518915a, topicName=心血管结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Fri Nov 19 03:29:17 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614791, encodeId=ebb41614e9161, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Fri Nov 19 03:29:17 CST 2021, time=2021-11-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1939272, encodeId=223f19392e2f6, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Oct 07 06:29:17 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761774, encodeId=e3731e6177484, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Aug 02 19:29:17 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639971, encodeId=ca7016399e11a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Dec 01 16:29:17 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812547, encodeId=8a57181254e40, content=<a href='/topic/show?id=4ce08986996' target=_blank style='color:#2F92EE;'>#血红蛋白A1c#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89869, encryptionId=4ce08986996, topicName=血红蛋白A1c)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Feb 10 03:29:17 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269393, encodeId=9973126939344, content=<a href='/topic/show?id=49d1518915a' target=_blank style='color:#2F92EE;'>#心血管结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51891, encryptionId=49d1518915a, topicName=心血管结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Fri Nov 19 03:29:17 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614791, encodeId=ebb41614e9161, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Fri Nov 19 03:29:17 CST 2021, time=2021-11-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1939272, encodeId=223f19392e2f6, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Oct 07 06:29:17 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761774, encodeId=e3731e6177484, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Aug 02 19:29:17 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639971, encodeId=ca7016399e11a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Dec 01 16:29:17 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812547, encodeId=8a57181254e40, content=<a href='/topic/show?id=4ce08986996' target=_blank style='color:#2F92EE;'>#血红蛋白A1c#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89869, encryptionId=4ce08986996, topicName=血红蛋白A1c)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Feb 10 03:29:17 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269393, encodeId=9973126939344, content=<a href='/topic/show?id=49d1518915a' target=_blank style='color:#2F92EE;'>#心血管结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51891, encryptionId=49d1518915a, topicName=心血管结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Fri Nov 19 03:29:17 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614791, encodeId=ebb41614e9161, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Fri Nov 19 03:29:17 CST 2021, time=2021-11-19, status=1, ipAttribution=)]

相关资讯

Heart:慢性冠心病或外周动脉疾病患者停用小剂量利伐沙班的心血管结局

停止利伐沙班和阿司匹林组合治疗转为阿司匹林单药治疗与心血管益处丢失和卒中增加相关。

JAHA:QT间期动态变化与心血管结局

使用来自连续心电图检查的纵向信息可以提高对CVD结局的预测能力。与线性斜率或均方根误差相比,校正的长期平均QT与CVD结局的相关性更强。这一新证据具有临床意义,因为心电图经常使用、无创且价格低廉。

Diabetologia :新型降糖药物对心血管结局的有效性和安全性

最近发布了一些关于钠-葡萄糖共转运体2抑制剂(SGLT2i)的心血管结局试验,包括纳入充血性心力衰竭(CHF)和慢性肾脏疾病(CKD)患者的试验。

JAHA:乳腺癌治疗后心血管结局风险评分模型的开发和验证

该研究开发并验证了预测评分模型,包括BC治疗相关的危险因素和常规危险因素,以预测BC患者的主要不良心血管事件。

JCEM:接受甲状腺切除术的甲状腺癌患者心血管结局

DTC患者发生房颤、CVD、心率加快和左心室质量增重的风险增加。

JAHA:2型糖尿病患者的钠-葡萄糖协同转运蛋白2抑制剂、全因死亡率和心血管结局

与安慰剂相比,恩格列净、卡格列净和达格列净降低了全因死亡率和心血管死亡率的发生率。钠-葡萄糖协同转运蛋白2抑制剂与安慰剂的治疗效果不因基线风险而异。

Baidu
map
Baidu
map
Baidu
map